Navigation Links
JDRF funded research shows promise for prevention, reversal of type 1 diabetes

New York, NY, November 18, 2008 -- Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice. The JDRF-funded study, published in The Proceedings of the National Academy of Sciences, was led by Jeffrey Bluestone, Ph.D., director of the Diabetes Center at UCSF and an expert in the field of autoimmunity.

"The findings suggest that kinase inhibitors successfully used in cancer may provide an important new therapeutic approach for treatment of new onset type 1 diabetes and potentially other autoimmune disorders," said JDRF Director of Immunology Teodora Staeva, Ph.D.

The drugs Imatinib and Sunitnib, sold as Gleevec and Sutent, respectively are used to treat cancer by blocking tyrosine kinases, an enzyme that modify cells' signaling proteins through a simple biochemical change. Kinases trigger cell growth, and it is widely believed that tyrosine kinases are a contributing factor to autoimmune diseases and cancer. The researchers hypothesized that tyrosine kinases may also serve as a trigger to the body's attack on the immune system.

The researchers at the University of California, San Francisco treated non-diabetic mice prone to developing diabetes with imatinib or sunitinib, and found that the drugs prevented the onset of diabetes past the seven-week treatment. Mice that already developed diabetes were treated with the drugs and results concluded that after two months of treatment, 80 percent no longer had diabetes.


Contact: Jillian Lubarsky
Juvenile Diabetes Research Foundation International

Page: 1

Related biology news :

1. Mandate for public access to NIH-funded research poised to become law
2. Irritating smells alert special cells, NIH-funded study finds
3. OSU technologies funded for development
4. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
5. JDRF funded study links hygiene hypothesis to diabetes prevention
6. Research shows skeleton to be endocrine organ
7. Newly created cancer stem cells could aid breast cancer research
8. Dominant cholesterol-metabolism ideas challenged by new research
9. Researchers identify proteins involved in new neurodegenerative syndrome
10. Texas researchers and educators head for Antarctica
11. MGH researchers describe new way to identify, evolve novel enzymes
Post Your Comments:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
Breaking Biology Technology: